Lineage Cell Therapeutics, Inc. (LCTX) Free cash flow 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$19.4MFY2025 · since FY2016: -$44.6M → -$19.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$19.4M | +17.8% |
| FY2024 | -$23.7M | +19.1% |
| FY2023 | -$29.2M | -4626.3% |
| FY2022 | $646,000 | +102.7% |
| FY2021 | -$23.9M | -20.6% |
| FY2020 | -$19.8M | +38.8% |
| FY2019 | -$32.4M | -3.0% |
| FY2018 | -$31.4M | +1.3% |
| FY2017 | -$31.8M | +28.6% |
| FY2016 | -$44.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice